Osteoporosis: Bone Loss, Fracture Risk, Diagnosis, and Treatment

Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural deterioration, leading to increased fragility and fracture risk.

Pathophysiology

Imbalance between osteoclast-mediated resorption and osteoblast-mediated formation. Postmenopausal estrogen loss accelerates resorption. Aging reduces osteoblast activity. Result: thinner cortices, trabecular loss, connectivity loss.

Clinical Features

  • Silent until fracture (hip, vertebral, wrist, humerus).
  • Vertebral fractures: height loss, kyphosis, chronic back pain.
  • Hip fracture: high morbidity/mortality (20–30% 1-year mortality).

Diagnosis

  • DXA (dual-energy X-ray absorptiometry): T-score ≤ -2.5 at hip/spine = osteoporosis. T-score -1 to -2.5 = osteopenia.
  • FRAX® tool: 10-year major osteoporotic/hip fracture probability (incorporates clinical risk factors).

Pharmacotherapy

  • Antiresorptives: Bisphosphonates (alendronate, zoledronate), denosumab (RANKL inhibitor), raloxifene (SERM).
  • Anabolics: Teriparatide, abaloparatide (PTH analogs), romosozumab (sclerostin inhibitor) — build bone; limited to 12–24 months.

Non-Pharmacological

  • Weight-bearing/resistance exercise.
  • Calcium 1000–1200 mg/day (diet + supplement), Vitamin D 800–2000 IU/day.
  • Fall prevention: home safety, vision check, balance training.
  • Smoking cessation, alcohol moderation.

Prevention

Peak bone mass (age 25–30) sets trajectory. Lifelong adequate calcium/D, exercise, avoiding smoking/excess alcohol maximizes peak and slows loss.

Osteoporosis - Related Articles